Zindoxifene | CAS#86111-26-4 | antineoplastic

MedKoo Cat#: 584368 | Name: Zindoxifene

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Zindoxifene has been found to have anti-neoplastic activity in androgen-dependent prostatic tumors in rats.

Chemical Structure

Zindoxifene

CAS#86111-26-4

Theoretical Analysis

MedKoo Cat#: 584368

Name: Zindoxifene

CAS#: 86111-26-4

Chemical Formula: C21H21NO4

Exact Mass: 351.1471

Molecular Weight: 351.40

Elemental Analysis: C, 71.78; H, 6.02; N, 3.99; O, 18.21

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Zindoxifene; D 16726

IUPAC/Chemical Name

1-Ethyl-2-(p-hydroxyphenyl)-3-methylindol-5-ol diacetate (ester)

InChi Key

KSZGVNZSUJHOJA-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H21NO4/c1-5-22-20-11-10-18(26-15(4)24)12-19(20)13(2)21(22)16-6-8-17(9-7-16)25-14(3)23/h6-12H,5H2,1-4H3

SMILES Code

CC1=C(C2=CC=C(OC(C)=O)C=C2)N(CC)C3=C1C=C(OC(C)=O)C=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 351.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Stein RC, Dowsett M, Cunningham DC, Davenport J, Ford HT, Gazet JC, von Angerer E, Coombes RC. Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study. Br J Cancer. 1990 Mar;61(3):451-3. PubMed PMID: 2328214; PubMed Central PMCID: PMC1971274. 2: Schneider MR, Schiller CD, Humm A, von Angerer E. Effect of zindoxifene on experimental prostatic tumours of the rat. J Cancer Res Clin Oncol. 1991;117(1):33-6. PubMed PMID: 1997466. 3: von Angerer E, Prekajac J, Berger M. The inhibitory effect of 5-acetoxy-2-(4-acetoxyphenyl)-1-ethyl-3-methylindole (D 16726) on estrogen-dependent mammary tumors. Eur J Cancer Clin Oncol. 1985 Apr;21(4):531-7. PubMed PMID: 3924626. 4: von Angerer E, Birnböck H, Kager M, Maucher A. The effect of a combination of zindoxifene and cisplatin on Dunning R3327-G prostatic carcinomas of the rat. J Cancer Res Clin Oncol. 1992;118(5):339-43. PubMed PMID: 1583065. 5: Alba E, Ragonesi G, Colla F, Mazzoleni A, Farina C. [Antiestrogen therapy in the treatment of breast neoplasms]. Minerva Ginecol. 2002 Jun;54(3):245-51. Review. Italian. PubMed PMID: 12063440. 6: Schneider MR, von Angerer E, Höhn W, Sinowatz F. Antitumor activity of antiestrogenic phenylindoles on experimental prostate tumors. Eur J Cancer Clin Oncol. 1987 Jul;23(7):1005-15. PubMed PMID: 3665986. 7: Csapo Z, Brand K, Schrott KM, Schwindl B. Prostatic acid phosphatase in the serially transplantable human prostatic tumor lines PC-82 and PC-EW. Urol Res. 1990;18(2):137-42. PubMed PMID: 2339482. 8: Jordan VC, Tormey DC. Antiestrogen therapy for breast cancer: current strategies and future prospects. Cancer Treat Res. 1988;39:97-110. Review. PubMed PMID: 2908611. 9: von Angerer E. Development of new drugs for endocrine tumour chemotherapy. Cancer Treat Rev. 1984 Mar;11 Suppl A:147-53. PubMed PMID: 6547370. 10: Hilgard P, Pohl J, Engel J. The development of alkylphosphocholines as signal transduction inhibitors: experimental and clinical challenges. J Cancer Res Clin Oncol. 1997;123(5):286-7. PubMed PMID: 9201252. 11: Birnböck H, Ringshandl R, von Angerer E. Chromatographic analysis of the new antiestrogen zindoxifene and its metabolites in biological material. J Chromatogr. 1987 Feb 20;414(1):235-41. PubMed PMID: 3571389. 12: Schiller CD, von Angerer E, Schneider MR. 6,7-Dihydro-4H-indolones: synthesis and biological properties. Arch Pharm (Weinheim). 1991 Oct;324(10):767-71. PubMed PMID: 1805709. 13: Robinson SP, Koch R, Jordan VC. In vitro estrogenic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in vivo. Cancer Res. 1988 Feb 15;48(4):784-7. PubMed PMID: 3338076.